Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms, Male × ribociclib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 52 Neoplasm Metastasis 5 Neoplasms 4 Endometrial Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Ovarian Neoplasms 3 Melanoma 3 Glioma 3 Colorectal Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Neuroblastoma 2 Neoplasms by Site 2 Lung Neoplasms 2 Glioblastoma 2 Breast Diseases 2 Brain Neoplasms 2 Venous Thromboembolism 1 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Sarcoma 1 Rhabdomyosarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Medulloblastoma 1 Locoregional Recurrence 1

Interventions

Taxes 4 Paclitaxel 3 Cyclophosphamide 3 exemestane 2 Tamoxifen 2 Leuprolide 2 Letrozole 2 Immunotherapy 2 Goserelin 2 Doxorubicin 2 Anastrozole 2 trastuzumab biosimilar HLX02 1 romidepsin 1 ribociclib 1 pegfilgrastim 1 entinostat 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abemaciclib 1 Vitamins 1 Trastuzumab 1 Psychiatric Rehabilitation 1 PF-05280014 1 Ontruzant 1 Omeprazole 1 Ogivri 1 Neoadjuvant Therapy 1 Mental Status and Dementia Tests 1 Lapatinib 1 Indomethacin 1 Immunoglobulin G 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05827081 2026-03-02

Adjuvant WIDER

Novartis

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡